세계의 제네릭 의약품 시장 : 적응증(중추신경계, 심혈관, 비뇨기과, 종양학, 호흡기, 기타), 투여 경로, 유통 채널, 지역별(-2035년)

Global Generic Drugs Market Research Report by Indication (Central Nervous System (CNS), Cardiovascular, Urology, Oncology, Respiratory, Others), by Route of Administration (Oral, Topical, Parenteral, Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and by Region (North America, Europe, Aia-Pacific, Rest of the World) Forecast till 2035

Industry Overview

The global generic drugs market is expected to nearly triple to USD 1,148.55 billion by 2035, driven by steady annual growth of 9.36%. A generic drug is a pharmaceutical product equivalent in dosage, strength, safety, and intended use to a branded medicine but sold under its chemical name. These drugs are typically marketed after patent protection ends, making them a cost-effective option for patients and healthcare systems.

The prevalence of chronic illnesses has been identified as a significant factor contributing to the growth of the global generic medication market. Cancer, heart disease, and other conditions like these have increased dramatically, and this is the case with the rise of epilepsy and arthritis, resulting in the need for low-cost treatment. Generic medicines deliver therapeutic benefits similar to those of branded drugs but at a much lower price; therefore, they become the only option for patients and healthcare systems that face difficult situations with their budgets. The players of the market are intensifying their supply by launching new products, extending their existing facilities, and entering into new therapeutic areas.

Nevertheless, voluntary product recalls caused by quality or safety issues remain a major obstacle to the availability of products and confidence in generics. Brand loyalty of healthcare professionals is one of the factors that limits wider adoption. Those who have not changed their minds still continue prescribing the branded medicines that they are familiar with to the patients.

At the same time, the act of allocating money to R&D allows the production of high-quality generics, which includes the implementation of advanced technology and the expansion of the market reach. The increasing age of the world population is one of the key factors that pushes up senior consumers, who make up a large portion of the market for chronic disease medication. By 2050, the old people in the Asia-Pacific is expected to be twice as many as they are now; therefore, affordable medicines will be the topmost issue. If these trends, combined with favorable government policies, continue to prevail, generic drugs will remain at the forefront of providing global healthcare.

Industry Segmentations

In terms of indication, the global drugs market is segmented into central nervous system (CNS), cardiovascular, urology, oncology, respiratory, and others.

The global market is classified based on the route of administration, comprising oral, topical, parenteral, and others.

Depending on the distribution channel, the global generic drug market is divided into hospital, retail, and online pharmacy.

Regional Analysis

In North America, the generic drugs market is bolstered by the need to control rising healthcare costs. The US is the leader in the region with a vast network of manufacturers and a legal framework that is clearly defined and enables patent expiry and generic substitution. Patient acceptance of generics, which is growing, has made it possible to keep a strong sales record, especially in cardiovascular, oncology, and antibiotic segments. Canadian healthcare policies that promote cost efficiency are hence one of the factors that allow generics to be steadily taken up.

Europe's market is reaping the benefits from a regulatory environment that is clear and the presence of a strong public healthcare system that emphasizes affordability. Germany, Spain, and the UK are among the top consumers of this product, and their national health services are promoting generic prescriptions. The improvement in medicine accessibility, along with the increasing numbers of the middle-class population, are the main factors driving the catching up of Eastern European countries. Competitive pricing and supportive legislation are key growth factors in the region.

Asia-Pacific is the fastest-growing region, and most of the growth is coming from the manufacturing potential of Asia, particularly India and China. India is a global leader in supplying the highest quality generics at the most reasonable prices, and China's market is receiving the positive impact of healthcare reforms on a large scale. Due to demographic changes in the age structure of the population and rising prevalence of chronic diseases, the demand for cheap drugs has increased. Besides South Korea and Thailand, these countries are also among the most prolific users of generic medicine to reduce the cost of healthcare.

Latin America, the Middle East, and Africa are an increasing part of the generic medicines market on a global scale. With Brazil, there is a more aggressive push to increase local production, while Mexico benefits from cross-border trade with the US. Rising investment in pharmaceutical manufacturing in the Middle East is contributing to the region's effort to become more self-sufficient. African countries are setting the availability of drugs and the strengthening of distribution channels for generics as their top priorities.

Key Players

Major players in the global generic drugs market are Teva Pharmaceuticals Industries Ltd., Novartis AG, Viatris, Inc., Sun Pharmaceuticals Industries, Fresenius Kabi, Lupin Pharmaceuticals, Inc., Endo International plc, Aurobindo Pharma, Aspen Holdings, Cipla Ltd., and Fresenius SE & Co. KGaA.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

• 3.1 OVERVIEW
• 3.2 DATA FLOW
  • 3.2.1 DATA MINING PROCESS
• 3.3 PURCHASED DATABASE:
• 3.4 SECONDARY SOURCES:
  • 3.4.1 SECONDARY RESEARCH DATA FLOW:
• 3.5 PRIMARY RESEARCH:
  • 3.5.1 PRIMARY RESEARCH DATA FLOW:
  • 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
  • 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
• 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
  • 3.6.1 REVENUE ANALYSIS APPROACH
• 3.7 DATA FORECASTING
  • 3.7.1 DATA FORECASTING TYPE
• 3.8 DATA MODELING
  • 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
  • 3.8.2 DATA MODELING:
• 3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

• 4.1 INTRODUCTION
• 4.2 DRIVERS
  • 4.2.1 INCREASING INCIDENCES OF CHRONIC DISEASES ACROSS THE GLOBE
  • 4.2.2 RISING STRATEGIC INITIATIVES BY MARKET PLAYERS
  • 4.2.3 RISING DEMAND FOR AFFORDABLE MEDICATIONS
• 4.3 RESTRAINTS
  • 4.3.1 VOLUNTARY PRODUCT RECALLS FROM MARKET PLAYERS
  • 4.3.2 BRAND LOYALTY AND DOCTOR PREFERENCES
• 4.4 OPPORTUNITY
  • 4.4.1 INVESMTENT ON RESEARCH & DEVELOPMENT (R&D) FOR GENERIC MEDICINE
  • 4.4.2 RISING AGING POPULATION

5 MARKET FACTOR ANALYSIS

• 5.1 PORTER'S FIVE FORCES MODEL
  • 5.1.1 THREAT OF NEW ENTRANTS
  • 5.1.2 BARGAINING POWER OF SUPPLIERS
  • 5.1.3 THREAT OF SUBSTITUTES
  • 5.1.4 BARGAINING POWER OF BUYERS
  • 5.1.5 INTENSITY OF RIVALRY
• 5.2 IMPACT OF COVID-19 ON THE GLOBAL GENERIC DRUGS MARKET

6 GLOBAL GENERIC DRUGS MARKET, BY INDICATION

• 6.1 OVERVIEW
• 6.2 CENTRAL NERVOUS SYSTEM (CNS)
• 6.3 CARDIOVASCULAR
• 6.4 UROLOGY
• 6.5 ONCOLOGY
• 6.6 RESPIRATORY
• 6.7 OTHERS

7 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION

• 7.1 OVERVIEW
• 7.2 ORAL
• 7.3 TOPICAL
• 7.4 PARENTERAL
• 7.5 OTHERS

8 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL

• 8.1 OVERVIEW
• 8.2 HOSPITAL PHARMACY
• 8.3 RETAIL PHARMACY
• 8.4 ONLINE PHARMACY

9 GLOBAL GENERIC DRUGS MARKET, BY REGION

• 9.1 OVERVIEW
• 9.2 NORTH AMERICA
  • 9.2.1 US
  • 9.2.2 CANADA
• 9.3 EUROPE
  • 9.3.1 GERMANY
  • 9.3.2 FRANCE
  • 9.3.3 UK
  • 9.3.4 ITALY
  • 9.3.5 SPAIN
  • 9.3.6 REST OF EUROPE
• 9.4 ASIA-PACIFIC
  • 9.4.1 CHINA
  • 9.4.2 INDIA
  • 9.4.3 JAPAN
  • 9.4.4 SOUTH KOREA
  • 9.4.5 AUSTRALIA
  • 9.4.6 REST OF ASIA-PACIFIC
• 9.5 REST OF THE WORLD
  • 9.5.1 MIDDLE EAST
  • 9.5.2 AFRICA
  • 9.5.3 SOUTH AMERICA

10 COMPETITIVE LANDSCAPE

• 10.1 INTRODUCTION
• 10.2 MARKET SHARE ANALYSIS, 2024
• 10.3 COMPETITOR DASHBOARD
• 10.4 PUBLIC PLAYERS STOCK SUMMARY
• 10.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
• 10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 10.6.1 PRODUCT LAUNCH
  • 10.6.2 PRODUCT LAUNCH / PRODUCT APPROVAL
  • 10.6.3 EXPANSION

11 COMPANY PROFILES

• 11.1 SUN PHARMACEUTICAL INDUSTRIES LTD.
  • 11.1.1 COMPANY OVERVIEW
  • 11.1.2 FINANCIAL OVERVIEW
  • 11.1.3 PRODUCTS OFFERED
  • 11.1.4 KEY DEVELOPMENTS
  • 11.1.5 SWOT ANALYSIS
  • 11.1.6 KEY STRATEGIES
• 11.2 LUPIN PHARMACEUTICALS, INC.
  • 11.2.1 COMPANY OVERVIEW
  • 11.2.2 FINANCIAL OVERVIEW
  • 11.2.3 PRODUCTS OFFERED
  • 11.2.4 KEY DEVELOPMENTS
  • 11.2.5 SWOT ANALYSIS
  • 11.2.6 KEY STRATEGIES
• 11.3 ENDO INTERNATIONAL PLC
  • 11.3.1 COMPANY OVERVIEW
  • 11.3.2 FINANCIAL OVERVIEW
  • 11.3.3 PRODUCTS OFFERED
  • 11.3.4 KEY DEVELOPMENTS
  • 11.3.5 KEY STRATEGIES
• 11.4 AUROBINDO PHARMA
  • 11.4.1 COMPANY OVERVIEW
  • 11.4.2 FINANCIAL OVERVIEW
  • 11.4.3 PRODUCTS OFFERED
  • 11.4.4 KEY DEVELOPMENTS
  • 11.4.5 KEY STRATEGIES
• 11.5 ASPEN HOLDINGS
  • 11.5.1 COMPANY OVERVIEW
  • 11.5.2 FINANCIAL OVERVIEW
  • 11.5.3 PRODUCTS OFFERED
  • 11.5.4 KEY DEVELOPMENTS
  • 11.5.5 KEY STRATEGIES
• 11.6 CIPLA LTD
  • 11.6.1 COMPANY OVERVIEW
  • 11.6.2 FINANCIAL OVERVIEW
  • 11.6.3 PRODUCTS OFFERED
  • 11.6.4 KEY DEVELOPMENTS
  • 11.6.5 SWOT ANALYSIS
  • 11.6.6 KEY STRATEGIES
• 11.7 NOVARTIS AG
  • 11.7.1 COMPANY OVERVIEW
  • 11.7.2 FINANCIAL OVERVIEW
  • 11.7.3 PRODUCTS OFFERED
  • 11.7.4 KEY DEVELOPMENTS
  • 11.7.5 SWOT ANALYSIS
  • 11.7.6 KEY STRATEGIES
• 11.8 TEVA PHARMACEUTICAL INDUSTRIES LTD
  • 11.8.1 COMPANY OVERVIEW
  • 11.8.2 FINANCIAL OVERVIEW
  • 11.8.3 PRODUCTS OFFERED
  • 11.8.4 KEY DEVELOPMENTS
  • 11.8.5 SWOT ANALYSIS
  • 11.8.6 KEY STRATEGIES
• 11.9 FRESENIUS SE & CO. KGAA
  • 11.9.1 COMPANY OVERVIEW
  • 11.9.2 FINANCIAL OVERVIEW
  • 11.9.3 PRODUCTS OFFERED
  • 11.9.4 KEY DEVELOPMENTS
  • 11.9.5 KEY STRATEGIES
• 11.10 VIATRIS INC.
  • 11.10.1 COMPANY OVERVIEW
  • 11.10.2 FINANCIAL OVERVIEW
  • 11.10.3 PRODUCTS OFFERED
  • 11.10.4 KEY DEVELOPMENTS
  • 11.10.5 KEY STRATEGIES

12 DATA CITATIONS